Bristol-Myers Squibb is a biopharmaceutical company that specializes in oncology, immunology and cardiovascular therapeutics. The company's leading drugs include blood thinner Eliquis, lung cancer drug Opdivo and multiple myeloma drug Pomalyst. Hardy says Bristol-Myers shares are attractively valued relative to its improving growth outlook. The company recently acquired psychiatric and neurological conditions specialist Karuna Therapeutics, and Hardy says Bristol-Myers will continue to diversify its business in the next several years. He says an improving sales growth trajectory could offset risks to Eliquis sales in 2026 and beyond. CFRA has a "buy" rating and $60 price target for BMY stock, which closed at $58.69 on Dec. 3.